Update shared on15 Aug 2025
Marchex’s modestly higher future P/E ratio and slight weakening in net profit margin suggest incrementally greater valuation risk, but the consensus price target remains unchanged at $4.00.
What's in the News
- Marchex launched an AI-powered healthcare solution to provide health systems and marketing organizations with actionable insights from patient conversations, enhancing attribution, appointment prioritization, and marketing optimization.
- Marchex's Marketing Edge is now available on Microsoft Azure Marketplace and AppSource, offering AI-driven call tracking and conversational analytics to help marketers optimize campaigns, understand customer interactions, and improve ROI.
- Marchex expanded its partnership with FordDirect, making its Engage for Sales and Service solution available to nearly 3,000 Ford and Lincoln dealerships, enabling advanced AI insights for sales, service optimization, customer sentiment tracking, and revenue growth.
Valuation Changes
Summary of Valuation Changes for Marchex
- The Consensus Analyst Price Target remained effectively unchanged, at $4.00.
- The Future P/E for Marchex has risen slightly from 42.78x to 43.72x.
- The Net Profit Margin for Marchex has fallen slightly from 10.13% to 9.91%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.